Molecular imaging of gene expression and protein function in vivo with PET and SPECT

Journal of Magnetic Resonance Imaging

Volumn 16, Issue 4, 2002, Pages 336-351

  Sharma, Vijay ^a   Luker, Gary D ^a   Piwnica Worms, David ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluorodeoxyglucose; P glycoprotein; Positron emission tomography; Protein protein interactions; Reporter gene; Single photon emission computed tomography; Thymidine kinase

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CARBON 11; CARRIER PROTEIN; CHOLINE; CHOLINE KINASE; CONTRAST MEDIUM; COPPER 64; CYTOSINE DEAMINASE; DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; GALLIUM 68; GLYCOPROTEIN P; HEXOKINASE; INTEGRIN; NEUROTENSIN RECEPTOR; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; RECEPTOR PROTEIN; SODIUM IODIDE SYMPORTER; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; THYMIDINE KINASE; TRACER; TRANSACTIVATOR PROTEIN; YTTRIUM;

CELL MEMBRANE PERMEABILITY; CONTRAST ENHANCEMENT; GENE EXPRESSION; GENE REPRESSION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; MOLECULAR BIOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; CELL DIVISION; CHOLINE KINASE; GENE EXPRESSION; GENES, REPORTER; HEXOKINASE; HUMANS; IODINE; MONOSACCHARIDE TRANSPORT PROTEINS; NEOPLASMS; P-GLYCOPROTEINS; PROTEINS; RECEPTORS, SOMATOSTATIN; SYMPORTERS; THYMIDINE KINASE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036794547     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.10182     Document Type: Review

References (207)

1. Pennisi E. Human genome: finally, the book of life and instructions for navigating it. Science 2000;288:2304-2307.
2. Tavitian B, Terrazzino S, Kuhnast B, et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat Med 1998;4:467-471.
3. Krenning E, Kwekkeboom D, Bakker W. et al. Somatostatin receptor scintigraphy with [In-111-DTPA-D-Phe] and [I123-Tyr]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
4. Lister-James J, Vallabhajosula S, Moyer B, et al. Pre-clinical evaluation of technetium-99m platelet receptor-binding peptide. J Nucl Med 1997;38:105-111.
5. Perlmutter M, Slater S. Which nodular goiters should be removed? N Engl J Med 1956;255:61-71.
6. Luker GD, Piwnica-Wonns D. Beyond the genome: molecular imaging in vivo with PET and SPECT. Acad Radiol 2001;8:4-14.
7. Hom R, Katzenellenbogen J. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: recent developments and encouraging results. Nucl Med Biol 1997;24:485-498.
8. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999;99:2235-2268.
9. Anderson C, Welch M. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev 1999:99:2219-2234.
10. Volkert W, Hoffman T. Therapeutic radiopharmaceuticals. Chem Rev 1999;99:2269-2292.
11. Sharma V, Piwnica-Worms D. Metal complexes for therapy and diagnosis of drug resistance. Chem Rev 1999;99:2545-2560.
12. Eckelman W, Frank J, Brechbiel M. Theory and practice of imaging saturable binding sites. Invest Radiol 2002;37:101-106.
13. Grasby P. Imaging the neurochemical brain in health and disease. Clin Med 2002;2:67-73.
14. Piwnica-Worms D, Luker G, Anderson C, et al. Molecular imaging in oncology. In: Feinendegen LE, Shreeve WW, editors. Molecular nuclear medicine: the challenge from the human genome. Lansberg, Germany: Ecomed Publ., in press.
15. Warburg O. The metabolism of tumors. New York: Richard R. Smith, Inc.; 1931. p 1-129.
16. Brown R, Wahl R. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993;72:2979-2985.
17. Younes M, Lechago L, Somoano J, et al. Wide expression of the human erythrocyte glucose transporter Glut 1 in human cancers. Cancer Res 1996;56:1164-1167.
18. Clavo A, Brown R, Wahl R. 2-fluoro-2-deoxy-D-glucose (FDG) uptake into human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-1632.
19. Brown R, Leung J, Fisher S. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996;37:1042-1047.
20. Kubota K, Kubota R, Yamada S. FDG accumulation in tumor tissue. J Nucl Med 1993;34:419-421.
21. Aloj L, Caraco C, Jagoda E, et al. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999;59:4709-4714.
22. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551-1555.
23. Hoekstra C, Paglianiti I, Hoekstra O, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000;27:731-743.
24. Larson S, Grunbaum Z, Rasey J. Positron imaging faasibility studies: selective tumor concentration of 3H-thymidine, 3H-uridine, and 14C-2-deoxyglucose. Radiology 1980;134:771-773.
25. Wahl R, Hutchins G, Buchsbaum D, et al. 18F-2-deoxy-2-fluorod-glucose (FDG) uptake into human tumor xenografts: feasibility studies for cancer imaging with PET. Cancer 1991;67:1544-1550.
26. Wahl R, Zasadny K, Helvie M. et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography (PET): initial evaluation. J Clin Oncol 1993;11:2101-2111.
27. Evan G, Vousden K. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-348.
28. Christman D, Crawford E, Friedkin M, et al. Detection of DNA synthesis in intact organisms with positron-emitting methyl-[C-11]-thymidine. Proc Natl Acad Sci U S A 1972;69:988-992.
29. Vander Borght T, Labar D, Pauwels S, et al. Production of [2-C-11]thymidine for quantification of cellular proliferation with PET. Appl Radiat Isot 1991;42:103-104.
30. Conti P, Alauddin M, Fissekis J, et al. Synthesis of 2′-fluoro-5-[C-11]-methyl-1-beta-D-arabinofuranosyluricil ([C-11]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol 1995;22:783-789.
31. Krohn K, Mankoff D, Eary J. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001;41:96S-103S.
32. Shields A, Grierson J, Dohmen B, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Med 1998;4:1334-1336.
33. Conti P, Allauddin M, Fissekis J, et al. Synthesis of [F-18]2-fluoro-5-methyl-1-beta-D-arabinofuranosyluricil ([F-18]FMAU). J Nucl Med 1999;40:83P.
34. Buck A, Schirrmeister H, Hetzel M, et al. 3-deoxy-3-[F-18] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-3334.
35. de Certaines J, Larsen V, Podo F, et al. In vivo 31P MRS of experimental tumours. NMR Biomed 1993;6:345-365.
36. Katz-Brull R, Seger D, Rivenson-Segal D, et al. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002;62:1966-1970.
37. Hara T, Kosaka N, Kishi H. Development of F-18-fluoroethylchline for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002;43:187-199.
38. 11C]choline. J Nucl Med 1997;38:842-847.
39. DeGrado T, Coleman R, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110-117.
40. Price D, Coleman R, Liao R, et al. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002:168:273-280.
41. de-Herder W, Lamberts S. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002; 14:53-57.
42. Patel Y. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-198.
43. Reichlin S. Somatostatin (part 1). N Engl J Med 1983;309:1495-1501.
44. Reichlin S. Somatostatin (part 2). N Engl J Med 1983;309:1556-1563.
45. Bell G, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 1993;16:34-38.
46. Bruns C, Weckbecker G, Raulf F. Molecular pharmacology of somatostatin receptor subtypes. In: Wiedenmann B, Kvol L, Arnold R, Riecken E, editors. Molecular and cell biological cell aspects of gastroenteropancreatic tumor disease. New York: NY Academy of Sciences; 1994. p 138-147.
47. Vanetti M, Kouba M, Wang X, et al. Cloning and novel expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett 1992;311:290-294.
48. Patel Y, Amherdt M, Orci L. Quantitative electron microscopic autoradiography of insulin, glucagon, and somatostatic binding sites on islets. Science 1982;217:1155-1156.
49. Reubi J, Maurer R. Autoradiographic mapping of somatostatin receptors in the rat CNS and pituitary. Neuroscience 1985;15: 1183-1193.
50. Reubi J, Kvols L, Waser B. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell-carcinomas. Cancer Res 1990;50:5969-5977.
51. Sreedharan S, Kodama K, Peterson K, et al. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989;264:949-953.
52. Reubi J, Waser B, Foekens J. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 1990;46:416-420.
53. Reubi J, Waser B, Vanhagen M. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 1992;50:895-900.
54. Bakker WH, Albert R, Bruns C, et al. [111In-DTPA-D-Phe]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991;49:1583-1591.
55. Krenning EP, Bakker WH, Kooij PPM, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33:652-658.
56. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
57. Pearson DA, Lister-James J, McBride WJ, et al. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. J Med Chem 1996;39:1361-1371.
58. Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 1996;37:1016-1022.
59. 111Inoctreotide. J Nucl Med 2000;41:1114-1119.
60. 1-octreotide. Eur J Nucl Med 2000;27:628-637.
61. Anderson C, Pajeau T, Edwards W, et al. In vitro and in vivo evaluation of copper-64-octeotide conjugates. J Nucl Med 1995;36:2315-2325.
62. Anderson CJ, Dehdashti F, Cutler PD, et al. Copper-64-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001;42:213-221.
63. Smith-Jones PM, Stolz B, Bruns C, et al. Gallium-67/gallium-68-[DFO]-octreotide-a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radio-labeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35:317-325.
64. 1)-octreotide. a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol 1994;21:819-825.
65. Brockmann J, Rosch F, Herzog H, et al. In vivo uptake kinetics and dosimetry calculations of 86Y-DTPA-octreotide with PET as a model for potential endotherapeutic octreotides labelled with 90Y. J Labelled Compd Radiopharm 1993;37:319-321.
66. 86Y-DTPA-octreotide. Nucl Med Biol 1997;24:275-286.
67. Stolz B, Smith-Jones PM, Albert R, et al. Biological characterization of [67Ga] or [68Ga] labelled DFO-octreotide (SDZ-216-927) for PET studies of somatostatin receptor positive tumors. Horm Metab Res 1994;26:452-459.
68. 3-octreotide: first results in patients with meningiomas. J Nucl Med 2001;42:1053-1056.
69. Carraway R, Leeman S. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973;248:6854-6861.
70. Kitabgi P, Carraway R, Leeman S. Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J Biol Chem 1976;251:7053-7058.
71. Tyler-McMahon B, Boules M, Richelson E. Neurotensin: peptide for next millenium. Regul Pept 2000;93:125-136.
72. Ehlers R, Kim S, Zhang Y, et al. Gut peptide receptor expression in human pancreatic cancers. Ann Surg 2000;231:838-848.
73. Reubi J, Waser B, Friess H, et al. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 1998; 42:546-550.
74. Chalon P, Vita N, Kaghad M, et al. Molecular cloning of levocabastine-sensitive neurotensin binding site. FEBS Lett 1996;386:91-94.
75. Mazella J, Botto J, Guillemare E. et al. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J Neurosci 1996;16:5613-5620.
76. 2 receptor expressed in Chinese hampster ovary cells. Eur J Pharmacol 1998;360:265-272.
77. Mazella J, Zsurger N, Navarro V, et al. The 100-KDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem 1998;273:26273-26276.
78. Kitabgi P, Checkler F, Mazella J, et al. Pharmacology and biochemistry of neurotensin receptors. Rev Clin Basic Pharmacolv 1985;5:397-486.
79. 201T1(III)DTPA-neurotensin(8-13). J Labelled Compd Radiopharm 2000;43:1227-1234.
80. Chavatte K, Wong E, Fauconnier T, et al. Rhenium (Re) and technetium (Tc)-99m oxocomplexes of neurotensin(8-13). J Labelled Compd Radiopharm 1999;42:415-421.
81. Blauenstein P, Willmann M, Carrel-Remy N, et al. Pharmacological investigation of metabolically stablized peptides labeled with Technetium-99m [abstract]. Eur J Nucl Med 1999;26:1197.
82. Garcia-Garayoa E, Allemann-Tannahill L, Blauenstein P. et al. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors. Nucl Med Biol 2001;28:75-84.
83. 18F-labeled neurotensin(8-13) analogs. Nucl Med Biol 2002;29:61-72.
84. Eliceiri B, Cheresh D. Adhesion events in angiogenesis. Curr Opin Cell Biol 2001;13:563-568.
85. Haubner R, Wester H, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-336.
86. Breeman W, Hofland L, de Jong M, et al. Evaluation of radiolabelled Bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 1999;81:658-665.
87. Said S. Mutt V. Polypeptide with broad biological activity: isolation from the small intestine. Science 1970;69:1217-1218.
88. 99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nucl Med Biol 2001;28:445-450.
89. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 1996;23:685-692.
90. Fadok V, Bratton D, Rose D, et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000;405:85-90.
91. Tait J, Brown D, Gibson D, et al. Development and characterization of annexin V mutants with endogenous chelation for (99m)Tc. Bioconjug Chem 2000;11:918-925.
92. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A 1998;95:6349-6354.
93. Blankenberg F, Robbins R, Stoot J, et al. Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. Radiology 2000;214:795-800.
94. Narula J, Acio E, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001;7:1347-1352.
95. Pardridge W. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discovery 2002;1:131-139.
96. 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug Chem 1999;10:502-511.
97. Carrasco N. Iodide transport in the thyroid gland. Biochim Biophys Acta 1993;1154:65-82.
98. Tazebay U, Wapnir I, Levy O, et al. The mammary gland iodide trasnporter is expressed during lactation and in breast cancer. Nat Med 2000;6:871-878.
99. Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000;60:3484-3492.
100. Spitzweg C, Dietz A, O'Connor M, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001;8:1524-1531.
101. Haberkorn U. Gene therapy with sodium/iodide symporter in hepatocarcinoma. Exp Clin Endocrinol Diabetes 2001:109:60-62.
102. Huang M, Batra R, Kogai T, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001;8:612-618.
103. Moon D, Park K, Park K, et al. Correlation between 99mTc-pertechnetate uptakes and expressions of human sodium iodide symporter gene in breast tumor tissues. Nucl Med Biol 2001;28:829-834.
104. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-162.
105. Gros P, Ben Neriah Y, Croop JM, et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1996;323:728-731.
106. Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased mdrl expression can precede gene amplification. Science 1986;232:643-645.
107. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
108. Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1996;1288:F37-F54.
109. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
110. Flens MJ, Zaman GJR, van der Valk P, et al. Tissue distribution of multidrug resistance protein. Am J Pathol 1996;148:1237-1247.
111. Gottesman M, Fojo T, Bates S. Multidrug resistance in cancer: role of ATP-dependent transporters, Nat Rev Cancer 2002;2:48-58.
112. Keppler D, Leier I, Jedlitschky G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 1997;378:787-791.
113. Lautier D, Canitrot Y, Deeley R, et al. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 1996;52:967-977.
114. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance, Cancer Res 1993;53:1475-1479.
115. Doyle L, Yang W, Abruzzo L, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95:15665-15670.
116. Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes, Cancer Res 1999;59:8-13.
117. Allikmets R, Schrimi L, Hutchinson A, et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58:5337-5339.
118. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-199.
119. Gaveriaux C, Boesch D, Jachez B. PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 1991;2:225-234.
120. Hyafil F, Vergely C, Du Vignaud P, et al, In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53:4595-4602.
121. Dantzig A, Shepard R, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56:4171-4179.
122. Germann U, Ford P, Schlakhter D, et al. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209, and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 1997;8:141-155.
123. Rabindran S, He H, Singh M, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 1998;58:5850-5858.
124. Newman M, Rodarte J, Benbatoul K, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 2000;60:2964-2972.
125. Sorrentino B, Brandt S, Bodine D, et al, Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992;257:99-103.
126. Podda S, Ward M, Himelstein A, et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci U S A 1992;89:9676-9680.
127. Hanania E, Fu S, Roninson I, et al. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther 1995;2:279-284.
128. Moscow J, Huang H, Carter C, et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999;94:52-61.
129. Piwnica-Worms D. Functional identification of multidrug resistance gene expression in vivo. In: American Society of Clinical Oncology, Educational Book. Baltimore: Lippincott Williams & Wilkins; Spring 2000. p 178-184.
130. Piwnica-Worms D, Chiu M, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993:53:977-984.
131. Piwnica-Worms D, Rao V, Kronauge J, et al. Characterization of multidrug-resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 1995;34:12210-12220.
132. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Comm 1995;16:253-257.
133. Ballinger JR, Sheldon KM, Boxen I, et al. Differences between accumulation of Tc-99m-MIBI and Tl-201-thallous chloride in tumor cells: role of P-glycoprotein. Q J Nucl Med 1995;39:122-128.
134. Cordobes M, Starzec A, Delmon-Moingeon L, et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996;37:286-289.
135. Herman LW, Sharma V, Kronauge JF, et al. Novel hexakis(areneisonitrile)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. J Med Chem 1995;38:2955-2963.
136. Ballinger JR, Bannerman J, Boxen I, et al. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996;37:1578-1582.
137. Luker G, Rao V, Crankshaw C. et al. Characterization of phosphine complexes of technetium (III) as transport substrates of the multidrug resistance (MDR1) P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Biochemistry 1997;36:14218-14227.
138. Ballinger J, Muzzammil T, Moore M. Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors. J Nucl Med 1997;38:1915-1919.
139. Crankshaw C, Marmion M, Luker G, et al. Novel Tc(III)-Q-complexes for functional imaging of the multidrug resistance (MDR1) P-glycoprotein. J Nucl Med 1998;39:77-86.
140. Chen W, Luker K, Dahlheimer J, et al. Effects of MDR1 and MDR3 P-glycoproteins, MRP1 and BCRP/MXR/ABCP on transport of Tc-99m-tetrofosmin. Biochem Pharmacol 2000;60:413-426.
141. Dyszlewski M, Blake H, Dalheimer J, et al. Characterization of a novel Tc-99m-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity. Mol Imaging 2001;1:24-35.
142. Piwnica-Worms D, Kronauge J, Chiu M. Uptake and retention of hexakis (2-methoxy isobutyl isonitrile) technetium(I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-1838.
143. Sharma V, Beatty A, Wey S-P, et al. Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo. Chem Biol 2000;7:335-343.
144. Hendrikse N, Franssen E, van der Graaf W, et al. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999;26:283-293.
145. Hendrikse N, de Vries EG, Eriks-Fluks L, et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 1999;59:2411-2416.
146. 11C-colchicine for PET imaging of multiple drug resistance. J Nucl Med 2000;41: 493-501.
147. Kiesewetter D, Eckelman W. Radiochemical synthesis of [18F] fluoropaclitaxel [abstract]. J Labelled Compd Radiopharm 2001;44: S903-S905.
148. Packard A, Barbarics E, Kronauge J, et al. Copper(II)diiminedioxime complexes for imaging multidrug resistance. In: Proceedings of the 215th American Chemical Society Meeting 1998, Washington, DC, Nucl-100.
149. Zweit J, Lewis J, Dearling J, et al. Copper-64-diphosphine complexes: potential PET tracers for the assessment of multidrug resistance in tumors [abstract]. J Nucl Med 1997;38:133P.
150. Blower P. Small coordination compounds as radiopharmaceuticals for cancer targeting. Transition Met Chem 1998;23:109-112.
151. Lewis J, Dearling J, Sosabowski J, et al. Copper bis(diphosphine)complexes: radiopharmaceuticals for detection of multidrug resistance in tumors by PET. Eur J Nucl Med 2000;27:638-646.
152. Bigott H, McCarthy D, Wust F, et al. Production. processing and uses of 94m-Tc. J Labelled Compd Radiopharm 2001;44:S119-S121.
153. Del Vecchio S, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug resistance (MDR1) phenotype by technetium-99m-sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997;24:150-159.
154. Del Vecchio S, Ciarmiello A, Pace L, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 1997:38:1348-1351.
155. Chen C, Meadows B, Regis J, et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m-sestamibi. Clin Cancer Res 1997;3:545-552.
156. Luker GD, Fracasso PM, Dobkin J, et al. Modulation of the multidrug resistance P-glycoprotein: detection with Tc-99m-sestamibi in vivo. J Nucl Med 1997;38:369-372.
157. Bom H, Kim Y. Lim S, et al. Dipyridamole modulated Tc-99m-sestamibi (mibi) scintigraphy: a predictor of response to chemotherapy in patients with small cell lung cancer [abstract]. J Nucl Med 1997;38:240P.
158. Kostakoglu L, Elahi N, Kirarli P, et al. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 1994:38:1003-1008.
159. Barbarics E, Kronauge J, Cohen D, et al. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 1998;58:276-282.
160. Kostakoglu L, Kirath P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998:39:228-234.
161. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium-99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998:16:1677-1683.
162. Fukumoto M, Yoshida D, Hayase N, et al. Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography study. Cancer 1999;86:1470-1479.
163. Nagamachi S, Jinnouchi S, Ohnishi T, et al. The usefulness of Tc-99m-MIBI for evaluating brain tumors: comparative study with Tl-201 and relation with P-glycoprotein. Clin Nucl Med 1999;24:765-772.
164. 99mTc-MIBI imaging in patients with lung cancer. J Nucl Med 2001;42:1476-1483.
165. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998;77:353-358.
166. Peck R, Hewett J, Harding M. et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 2001;19:3130-3141.
167. Wu A, Yazaki P, Tsai S, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A 2000;97:8495-8500.
168. Derossi D, Calvet S, Trembleau A, et al. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996;271:18188-18193.
169. Elliot G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997;88:223-233.
170. Kubota S, Siomi H, Satoh T, et al. Functional similarity of HIV-1 rev and HTLV-1 rex proteins: identification of a new nucleolar-targeting signal in rev protein. Biochem Biophys Res Comm 1989; 162:963-970.
171. Frankel A, Pabo C. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988;55:1189-1193.
172. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 1994:91:664-668.
173. Kip1 induces cell migration. Nat Med 1998;4:1449-1452.
174. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-16017.
175. Josephson L, Tung C-H, Moore A, et al. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 1999;10:186-191.
176. Polyakov V, Sharma V, Dahlheimer J, et al. Synthesis and characterization in vitro of membrane permeant peptide conjugates for imaging and radiotherapy. J Labelled Compd Radiopharm 1999; 42:S4-S6.
177. Polyakov V, Sharma V, Dahlheimer J, et al. Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy. Bioconjug Chem 2000;11:762-771.
178. Vocero-Akbani A, Heyden N, Lissy N, et al. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 1999;5:29-33.
179. Schwarze S, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-1572.
180. Herschman H, Barrio J, Satyamurthy N, et al. Progress toward in vivo imaging of reporter gene expression using positron emission tomography. In: American Society of Clinical Oncology, Educational Book, Spring 2000. Baltimore: Lippincott Williams & Wilkins, p 169-177.
181. Liang Q, Satyamurthy N, Barrio J, et al. Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther 2001;19:1490-1498.
182. Zinn K, Buchsbaum D, Chaudhuri T, et al. Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide
183. Hemminki A, Zinn K, Liu B, et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst 2002;94:741-749.
184. Zhang L, Adams J, Billick E, et al. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther 2002;5:223-232.
185. Maclaren D, Gambhir S, Satyamurthy N, et al. Repetitive, noninvasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999;6:785-791.
186. Yu Y, Annala A, Barrio J, et al. Quantification of target gene expression by imaging reporter gene expression in living animals. Nat Med 2000;6:933-937.
187. Chaudhuri T, Rogers B, Buchsbaum D, et al. A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts. Gynecol Oncol 2001;83:432-438.
188. Haberkorn U, Oberdorfer F, Gebert J, et al. Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine. J Nucl Med 1996;37:87-94.
189. Haubner R, Avril N, Hantzopoulos P, et al. In vivo imaging of herpes simplex virus type I thymidine kinase gene expression: early kinetics of radiolabelled FIAU. Eur J Nucl Med 2000;27:283-291.
190. Tomicic M, Thust R, Sobol R, et al. DNA polymerase β mediates protection of mammalian cells against ganciclovir-induced cytotoxicity and DNA breakage. Cancer Res 2001;61:7399-7403.
191. Saito Y, Price R, Rottenberg D, et al. Quantitative autoradiographic mapping of herpes simplex virus encephalitis with a radiolabeled antiviral drug. Science 1982;217:1151-1153.
192. Saito Y, Rubenstein R, Price R, et al. Diagnostic imaging of herpes simplex virus encephalitis using a radiolabeled antiviral drug: autoradiographic assessment in an animal model. Ann Neurol 1984;15:548-558.
193. 18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol 1998:25:175-180.
194. Blasberg R, Tjuvajev J. Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q J Nucl Med 1999;43:163-169.
195. Gambhir S, Barrio J, Herschman H, et al. Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol 1999;26:481-490.
196. Charziioannou A, Cherry S, Shao Y, et al. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J Nucl Med 1999;40:1164-1175.
197. Gambhir S, Barrio J, Phelps M, et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci U S A 1999;96:2333-2338.
198. Shao Y, Cherry S, Farahani K, et al. Simultaneous PET and MR imaging. Phys Med Biol 1997;42:1965-1970.
199. Hospers G, Calogero A, van Waarde A, et al. Monitoring of herpes simplex virus thymidine kinase enzyme activity using positron emission tomography. Cancer Res 2000;60:1488-1491.
200. Gambhir S, Bauer E, Black M, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A 2000;97:2785-2790.
201. Tjuvajev J, Chen S, Joshi A, et al. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res 1999;59:5186-5193.
202. Luker G, Luker K, Sharma V, et al. In vitro and in vivo characterization of a dual-function green fluorescent protein-HSV1-thymidine kinase reporter gene driven by the human elongation factor 1 α promoter. Mol Imaging 2001;1:65-73.
203. Ponomarev V, Doubrovin M, Lyddane C, et al. Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia 2001;3:480-488.
204. Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A 2001;98:9300-9305.
205. Luker G, Sharma V, Pica C, et al. Non-invasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci U S A 2002;99:6961-6966.
206. Braun K, Degen J, Sandgren E. Hepatocyte transplantation in a model of toxin-induced liver disease: variable therapeutic effect during replacement of damaged parenchema by donor cells. Nat Med 2000;6:320-326.
207. Green L, Yap C, Nguyen K, et al. Indirect monitoring of endogenous gene expression by positron emission tomography (PET) imaging of reporter gene expression in transgenic mice. Mol Imaging Biol 2002;4:71-81.